What were Gujarat Themis Biosyn Ltd's latest quarterly results?
Gujarat Themis Biosyn Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -7.7%
- Revenue Growth YoY: +7.5%
- Operating Margin: 49.0%
Gujarat Themis Biosyn Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 57.4. ROE: 21.7%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Gujarat Themis Biosyn Ltd's latest quarterly results (Dec 2025) show
Gujarat Themis Biosyn Ltd's current PE ratio is 57.4x.
Gujarat Themis Biosyn Ltd's price-to-book ratio is 10.4x.
Gujarat Themis Biosyn Ltd's fundamental strength based on key financial ratios
Gujarat Themis Biosyn Ltd has a debt-to-equity ratio of N/A.
Gujarat Themis Biosyn Ltd's return ratios over recent years
Gujarat Themis Biosyn Ltd's operating cash flow is positive (FY2025).
Gujarat Themis Biosyn Ltd's current dividend yield is 0.27%.
Gujarat Themis Biosyn Ltd's shareholding pattern (Dec 2025)
Gujarat Themis Biosyn Ltd's promoter holding has remained stable recently.
Gujarat Themis Biosyn Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Gujarat Themis Biosyn Ltd may be worth studying
Gujarat Themis Biosyn Ltd investment thesis summary:
Gujarat Themis Biosyn Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.